✦ LIBER ✦

Therapy of myelofibrosis (excluding JAK2 inhibitors)

✍ Scribed by Alessandro Rambaldi

Book ID: 107618984
Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 189 KB
Volume: 91
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0532-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy with JAK 1/2 inhibitors for myel

Therapy with JAK 1/2 inhibitors for myelofibrosis

✍ Franz Romeder MD, Richard Greil… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 277 KB

Myelofibrosis, JAK2 inhibitors and eryth

Myelofibrosis, JAK2 inhibitors and erythropoiesis

✍ Vainchenker, W; Favale, F 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 339 KB

Ruxolitinib, an oral JAK1 and JAK2 inhib

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Vaddi, Kris; Sarlis, Nicholas J; Gupta, Vikas 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 545 KB

JAK inhibitor therapy for myelofibrosis:

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

✍ Pardanani, A; Vannucchi, A M; Passamonti, F; Cervantes, F; Barbui, T; Tefferi, A 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 316 KB

Hypothesis: How do JAK2-inhibitors work

Hypothesis: How do JAK2-inhibitors work in myelofibrosis

✍ Ruben Mesa; Robert Peter Gale 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 205 KB

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and ot

Safety and Efficacy of INCB018424, a JAK

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cor 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 542 KB